Development of a Novel Anthrax Therapeutic

Anthrax still poses a major threat

Bacillus anthracis

Anthrax is a lethal disease caused by the bacterium Bacillus anthracis, which can spread by ingestion, inhalation, or cutaneous lesion contact of spores. This disease is not contagious, cannot be transferred from an infected organism, though bacterial spores can be transported in a multitude of ways and will infect potential victims. [1]

One of the primary reasons that Bacillus anthracis is such a deadly pathogen is its ability to evade the human immune system. The bacterium cloaks itself in an outer coat of poly-D-g-glutamic acid (PDGA) that confers antiphagocytic properties on the organism, and is essential for virulence [Antimicrobial Agents and Chemotherapy, January 2007, p. 215-222,Vol. 51, No. 1] .

The protective PDGA coat is synthesized on the surface of B. anthracis under the import of the transpeptidation enzyme CapD. During coat synthesis, a long strand of PDGA is first secreted, and then transferred to the peptidoglycan through a transpeptidation reaction catalyzed by CapD. It is important to note, however, that CapD has also been shown to have the capacity to catalyze hydrolysis of PDGA during this process, but at a rate much slower than the competing transpeptidation reaction.[reference]

This small amount of hydrolase activity was co-opted in a therapeutic capacity in a guinea pig model. When wild type CapD was overexpressed, the small amount of hydrolase activity inherent in the many copies of the enzyme that were produced was sufficient to compromise the protective coating of the bacterium. The immune system was then able to clear the infection much more effectively. We therefore hoped to engineer a mutant CapD protein for which the propensity to carry out a protective transpeptidation reaction was reduced, and the propensity to hydrolyze the protective coat was increased. If a mutant CapD with hydrolytic, rather than transpeptidation activity (which we term CapH) could be engineered, a single, highly concentrated dose of the protein in an infected individual could prove a potent therapeutic. Alternatively, simply ablating the protective transpeptidase activity without compromising the pre-existing hydrolase activity would likely dramatically increase the potency of this protein as a potential therapeutic.

Capsule Depolymerase (CapD):

Capsule Creator and Destroyer

Anthrax creates a poly-γ-D-glutamate (PDG) capsule which prevents the immune system from recognizing it as a pathogen and performing phagocytosis to eliminate the threat[Reference]. Researchs have shown that adding the enzyme capsule depolymerase to anthrax naturally, anthrax excretes a long strand of PDG and uses its CapD to cleave and anchor the PDG to its peptidoglycan, the outer coat of the cell membrane, as a protective capsule[Reference]. CapD can also cut and release its capsule into small pieces that can interfere with the immune responses.

Potential Weapon against Anthrax

Research based on a guinea pig model shows overexpression of CapD will destroy the capsule, removing anthrax's immunity to phagocytosis. CapD is naturally a transpeptidase, favoring reactions with amino acids to cleave PDG. However, CapD would be invaluable as a hydrolase, reacting efficiently with water, because of high water content in the human bloodstream. If a mutant CapD could be engineered as an extremely efficient hydrolase, it is theorized that a single dose of concentrated CapD into the blood stream would easily decimate anthrax populations, nullifying its lethal properties. [2]

References

1. Lucey DR, Anthrax. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 317.

2. Angelo Scorpio, Donald J Chabot, William A Day, Timothy A Hoover, and Arthur M Friedlander Capsule depolymerase overexpression reduces Bacillus anthracis virulence Microbiology 2010 : mic.0.035857-0v1-mic.0.035857-0. PMID: 20110296